Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Non-cash Items (2021 - 2024)

Inhibikase Therapeutics (IKT) has disclosed Non-cash Items for 4 consecutive years, with $8.0 million as the latest value for Q4 2024.

  • Quarterly Non-cash Items rose 1126.86% to $8.0 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $8.0 million through Dec 2024, up 1126.86% year-over-year, with the annual reading at $8.0 million for FY2024, 1126.86% up from the prior year.
  • Non-cash Items for Q4 2024 was $8.0 million at Inhibikase Therapeutics, up from $648979.0 in the prior quarter.
  • The five-year high for Non-cash Items was $8.0 million in Q4 2024, with the low at $300000.0 in Q4 2022.
  • Average Non-cash Items over 4 years is $3.1 million, with a median of $2.0 million recorded in 2021.
  • The sharpest move saw Non-cash Items plummeted 91.12% in 2022, then surged 1126.86% in 2024.
  • Over 4 years, Non-cash Items stood at $3.4 million in 2021, then tumbled by 91.12% to $300000.0 in 2022, then surged by 116.33% to $648979.0 in 2023, then soared by 1126.86% to $8.0 million in 2024.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $8.0 million, $648979.0, and $300000.0 for Q4 2024, Q4 2023, and Q4 2022 respectively.